GLOW Blend 70mg

GLOW Blend 70mg is a co-lyophilized research formulation containing 50mg GHK-Cu, 10mg BPC-157 and 10mg thymosin beta-4 per vial. It is supplied strictly for in-vitro and laboratory research.

The labeled total is 70mg: GHK-Cu 50mg, BPC-157 10mg and thymosin beta-4 10mg. The measured total for the current batch is in its lab report on this page.

The selected literature concerns the individual components. It should not be interpreted as direct evidence of synergy, equivalence or a proven combined effect for this fixed commercial formulation.

GHK-Cu is a copper-coordinated tripeptide investigated in fibroblast cultures, extracellular-matrix regulation, collagen-related endpoints and copper-dependent signaling. Those model-specific findings do not establish a clinical use.

BPC-157 and thymosin beta-4 have separate preclinical research records involving cell migration, angiogenesis-related pathways, actin binding and tissue-repair models. Human evidence is limited and no combined effect is asserted.

Every batch goes through three layers of quality control. Our manufacturer runs its own QC and has its production independently tested by Janoshik Analytical. Then Vanguard or Janoshik tests every batch we stock again, for identity, HPLC purity, net content and endotoxins before we approve it for sale.

Every approved batch has its lab report on the Test Results page.

GLOW contains three chemically distinct components. A single molecular weight, molecular formula or CAS number would incorrectly describe the blend as one chemical entity.

Keep the sealed lyophilized vial at −20°C, protected from light, and avoid repeated freeze-thaw cycles. Follow the product label and batch documentation. Prime Peptides release testing does not independently establish shelf life.